Increased expression of mineralocorticoid receptor and 11β- hydroxysteroid dehydrogenase type 2 in human atria during atrial fibrillation

Clinical Cardiology

Volumn 33, Issue 1, 2010, Pages 23-29

  Pei, De An ^a   Li, Li ^b   Xu, Zhi Yun ^b   Huang, Jin Yu ^a   Xu, Zheng Ming ^a   Wang, Min ^a   Yao, Qiang ^a   Huang, Shi Eng ^a  

^a HANGZHOU RED CROSS HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; MESSENGER RNA; MINERALOCORTICOID RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOPLASM; GENE EXPRESSION; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART MUSCLE CELL; HEART VALVE REPLACEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATIC HEART DISEASE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ADULT; ALDOSTERONE ANTAGONISTS; ATRIAL FIBRILLATION; FIBROSIS; HEART ATRIA; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RECEPTORS, MINERALOCORTICOID; RENIN-ANGIOTENSIN SYSTEM; RHEUMATIC HEART DISEASE; RNA, MESSENGER;

EID: 74949113938     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20689     Document Type: Article

References (23)

1. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002;106:331-336.
2. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation: Results of a prospective and controlled study. Eur Heart J. 2003;24:2090-2098.
3. Goette A, Hoffmanns P, Enayati W, et al. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol. 2001;88:906-909.
4. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248.
5. Yoshida M, Ma J, Tomita T, et al. Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure. Congest Heart Fail. 2005;11:12-16.
6. Pitt B, Zannad F, Remme WJ, et al. The effects of spironolactone on morbidity and mortality in patients with serve heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
7. Pitt B, Remme WJ, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
8. Farman N, Bocchi B. Mineralocorticoid selectivity: molecular and cellular aspects. Kidney Int. 2000;57:1364-1369.
9. Funder JW, Pearce PT, Smith R, et al. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 1988;242:583-585.
10. Draper N, Stewart PM. 11β-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol. 2005;186:251-271.
11. Qin W, Rudolph AE, Bond BR, et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res. 2003;93:69-76.
12. Spach MS. Mounting evidence that fibrosis generates a major mechanism for atrial fibrillation. Circ Res. 2007;101:743-745.
13. Everett TH IV, Olgin JE. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm. 2007;4:S24-S27.
14. Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with ventricular dysfunction. Circulation. 1999;100:376-380.
15. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the studies of left ventricular dysfunction (SOLVD) trials. Circulation. 2003;107:2926-2931.
16. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005; 45:712-719.
17. Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149:548-557.
18. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362: 772-776.
19. Connell JM, Davies E. The new biology of aldosterone. J Endocrinol. 2005;186:1-20.
20. Lombès M, Alfaidy N, Eugene E, et al. Prerequisite for aldosterone action. Mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase in the human heart. Circulation. 1995;92:175-182.
21. Konishi A, Tazawa C, Miki Y, et al. The possible of mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase type 2 in cardiac fibrosis in the spontaneously hypertensive rat. J Steroid Biochem Mol Biol. 2003;85:439-442.
22. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells. Circ Res. 2005;96: 643-650.
23. Shroff SC, Ryu K, Martovitz NL, et al. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol. 2006;17:534-541.